Joshua Brody, MD

Drs Park and Brody highlight the rapidly evolving treatment landscape for B-cell lymphomas, noting advances across frontline and relapsed settings.

Drs Park and Brody discuss the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma.

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like Burkitt lymphoma.

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.

Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.

Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.

An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.

Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.

Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.

Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.

Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).

Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Joshua Brody, MD, discusses Fas and its impact on bystander killing in patients with non-Hodgkin lymphoma.

Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.